Stock comparison
Eli Lilly
NeuroPace
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LLY
Eli Lilly
Market cap
$946.37B
Sector
Healthcare
NPCE
NeuroPace
Market cap
$536.42M
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LLY | NPCE | Winner |
|---|---|---|---|
| Warren Buffett | 65B | 30F | LLY |
| Benjamin Graham | 76B | 55C | LLY |
| Philip Fisher | 75B | 42D | LLY |
| Peter Lynch | 64C | 66B | NPCE |
| Joel Greenblatt | 68B | 0F | LLY |
| Charlie Munger | 75B | 28F | LLY |
| Terry Smith | 66B | 24F | LLY |
Side-by-side metrics
| Metric | LLY | NPCE |
|---|---|---|
| Market cap | $946.37B | $536.42M |
| P/E (TTM) | 35.6x | - |
| EV/EBIT | 33.2x | - |
| ROIC (TTM) | 32.06% | -19.74% |
| Gross margin | 83.51% | 78.29% |
| Net margin | 34.98% | -14.95% |
| Revenue CAGR 5y | 23.17% | 21.97% |
| EPS CAGR 5y | 40.81% | - |
| Debt / Equity | 1.4x | 4.9x |
| Dividend yield | 0.64% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- ROIC (TTM)32.06%vs -19.74%+162%
- Net margin34.98%vs -14.95%+143%
- Dividend yield0.64%vs 0.0%+100%
- Market cap$946.37Bvs $536.42M+100%
NPCE leads on
- P/E (TTM)-vs 35.6x+199%
- EV/EBIT-vs 33.2x+191%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.